Hypophosphatasia is a rare disease characterized by low serum levels of tissue non-specific alkaline phosphatase (TNSALP) and a spectrum of skeletal disease varying from the severest form with death in utero to mild with no clinical abnormality in adults. Currently, the diagnosis of hypophosphatasia is made on the basis of clinical findings, radiography, low serum alkaline phosphatase levels and raised abnormal phosphorylated metabolites ; there are elevations in serum pyridoxal 5h-phosphate, urinary phosphoethanolamine and inorganic pyrophosphate. In borderline cases the biochemical diagnosis remains uncertain. Prenatally, diagnosis is made using radiography and ultrasonography together with chorionic villus tissue biopsy, in which TNSALP levels are measured using an antibody-based assay. Since hypophosphatasia results from mutations in the TNSALP gene we have, for the first time in two U.K. families, undertaken restriction fragment length polymorphism (RFLP) analysis using three intragenic RFLPs for BclI and MspI at the ALPL locus. One family was informative, and a mutant-allele-specific haplotype with respect to three RFLPs was defined. In the other family the disease was shown to segregate with one allele of the BclI RFLP, but the MspI RFLPs were not informative. The disease segregated in the two families with different alleles of the BclI RFLP, suggesting that the mutations are likely to be different. We confirm that DNA analysis is likely to be the way ahead for diagnosing hypophosphatasia, and that standardized screening methods need to be developed for detecting mutations in these and other families.
A B S T R A C T
Hypophosphatasia is a rare disease characterized by low serum levels of tissue non-specific alkaline phosphatase (TNSALP) and a spectrum of skeletal disease varying from the severest form with death in utero to mild with no clinical abnormality in adults. Currently, the diagnosis of hypophosphatasia is made on the basis of clinical findings, radiography, low serum alkaline phosphatase levels and raised abnormal phosphorylated metabolites ; there are elevations in serum pyridoxal 5h-phosphate, urinary phosphoethanolamine and inorganic pyrophosphate. In borderline cases the biochemical diagnosis remains uncertain. Prenatally, diagnosis is made using radiography and ultrasonography together with chorionic villus tissue biopsy, in which TNSALP levels are measured using an antibody-based assay. Since hypophosphatasia results from mutations in the TNSALP gene we have, for the first time in two U.K. families, undertaken restriction fragment length polymorphism (RFLP) analysis using three intragenic RFLPs for BclI and MspI at the ALPL locus. One family was informative, and a mutant-allele-specific haplotype with respect to three RFLPs was defined. In the other family the disease was shown to segregate with one allele of the BclI RFLP, but the MspI RFLPs were not informative. The disease segregated in the two families with different alleles of the BclI RFLP, suggesting that the mutations are likely to be different. We confirm that DNA analysis is likely to be the way ahead for diagnosing hypophosphatasia, and that standardized screening methods need to be developed for detecting mutations in these and other families.
INTRODUCTION
Hypophosphatasia is a rare metabolic bone disease characterized by defective bone mineralization and low serum levels of tissue non-specific alkaline phosphatase (TNSALP) [1] . TNSALP is one of the four isoenzymes of alkaline phosphatase ; the others are intestinal, placental and placental-like (also known as germ cell type) alkaline phosphatases. The alkaline phosphatases are a group of membrane-bound glycoprotein enzymes that hydrolyse a range of monophosphate esters at an alkaline pH. They are widely distributed in animals and plants, and are present in virtually all mammalian tissues [2] . In humans, four separate genes encode the four different isoenzymes of alkaline phosphatase. Three of the genes, i.e. those encoding the placental, intestinal and germ cell alkaline phosphatase forms, are located on chromosome 2q34-2q37 [3] . TNSALP is encoded at the ALPL locus on chromosome 1p36.1-34 [4] . The ALPL gene is present as a single copy in the haploid genome and comprises 13 exons that are distributed over more than 50 kb of DNA [5, 6] . The enzyme itself is widely distributed and expressed in many tissues, and posttranslational modification in these tissues produces secondary TNSALP isoforms with different physiochemical properties [2] .
Hypophosphatasia has been classified into different clinical types : perinatal, infantile, childhood, adult, odontohypophosphatasia and pseudohypophosphatasia. In its severest form, death may occur in utero from skeletal malformation due to under-mineralization (perinatal form), while in its mildest form there may be very minor or no skeletal defects in adults. There is a disturbance of metabolism in a number of phosphorylated metabolites. Raised levels of serum pyridoxal 5h-phosphate, urinary phosphoethanolamine and inorganic pyrophosphate (PP i ) characteristically occur [1] .
Soon after hypophosphatasia was first described, it was recognized that this may be an inherited condition following the description of two affected siblings [7] . Although the mode of inheritance of the severe perinatal and infantile forms is more clear, and thought to be autosomal recessive, the mode of inheritance for the other and adult varieties of hypophosphatasia is less clear, and a dominant mode of inheritance has been suggested [1] . Hypophosphatasia is now known to result from mutations in the gene encoding TNSALP [8] .
Since its original description, the diagnosis of hypophosphatasia has been made on the basis of a combination of low levels of serum alkaline phosphatase activity, abnormal levels of the phosphorylated metabolites, radiography and the clinical features of the disease. As hypophosphatasia results from a defect in the gene for TNSALP, diagnoses have recently been made using DNA analysis [8] . In the U.K., to date, no attempts have yet been made to diagnose hypophosphatasia using DNA analysis. In two families with hypophosphatasia, we have had the opportunity of analysing DNA using restriction fragment length polymorphism (RFLP) analysis.
METHODS

Patients
Details of patients are given in Figures 1 and 2 and Table  1 . This research was carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association, and approval was obtained from the Ethical Committee of Leicestershire Health Authority to carry out diagnostic DNA tests for hypophosphatasia on these subjects. Informed consent was obtained from all subjects.
Family 1
The proband of this family (I-3) was diagnosed as having adult-onset hypophosphatasia with short stature (height Table 1 . 143 cm ; third centile). She presented at the age of 47 with bowing of her legs and a waddling gait. She was noted to have a deformed pelvis on radiography and had lost all her teeth by the age of 20 years. She had two daughters that had been delivered by Caesarean section, having had one male stillbirth. She had the characteristic biochemical features of hypophosphatasia. Total serum alkaline phosphatase activity was consistently low : mean serum alkaline phosphatase was 19 i.u.\l (n l 10 ; range 11-35 i.u.\l ; reference range 40-130 i.u.\l). The leucocyte alkaline phosphatase score was 0 (reference range 20-100). The serum pyridoxal 5h-phosphate concentration was 787 nmol\l (reference range 12-97 nmol\l). The full blood count was normal. A 24 h urine sample showed raised levels of PP i of 190 µmol\24 h (reference range 10-100 µmol\24 h), and in a spot urine sample the phosphoethanolamine concentration was 50 µmol\mmol of creatinine (reference levels 10 µmol\mmol). This patient has been reported previously to have persistently raised serum acid phosphatase activity [9] .
Other family members are shown in the pedigree (see Figures 1 and 2) . The brother of the proband (I-4 ; Figure  1 ), who died of an unknown cause at the age of 64 years, also had features of hypophosphatasia. He presented at the age of 53 with bone pain, and had a height of 152 cm. His biochemical results were : serum alkaline phosphatase, 21 i.u.\l (mean of four results) ; leucocyte alkaline phosphatase score, 0 ; 24 h urine phosphoethanolamine, 257 µmol\24 h (mean of four results). Details for his wife (II-5 ; Figure 1 ) are not available, but as far as is known she had no bone disease. One of the daughters of the proband (II-2 ; Figures 1 and 2) , for whom samples were available for DNA analysis, had biochemical features of hypophosphatasia (see Table 1 for details). The other daughter, aged 37 years (not shown on the family pedigree), also had biochemical features of hypophosphatasia (serum alkaline phosphatase 28 i.u.\l), but samples were not available for DNA analysis. It has not been possible to obtain samples for biochemical analysis from the sister (I-1) or granddaughter (III-1) of the index case, although samples were obtained for DNA analysis (see Figures 1 and 2) .
The pattern of inheritance of hypophosphatasia in Family 1 is consistent with the autosomal dominant mode.
Family 2
The proband (II-3 ; Figures 1 and 2 ) was a female presenting at the age of 20 years with bone pain and pyrophosphate arthropathy. She had one episode of severe right forearm bone pain, and X-rays showed a pseudo-fracture of the right radius. Biochemical findings were : serum alkaline phosphatase, 17 i.u.\l ; pyridoxal 5h-phosphate, 284 nmol\l ; leucocyte alkaline phosphatase score, 0. In a spot urine sample, the phosphoethanolamine concentration was 21 µmol\mmol of creatinine, and the PP i concentration was 16 µmol\mmol of creatinine (reference levels 5 µmol\mmol). The full blood count was normal. Other family members are shown in the family pedigree (Figures 1 and 2 ). Only the proband had clinical features of hypophosphatasia. Her father (I-2) and brother (II-2), although not having clinical features of hypophosphatasia in the form of bone pain or deformity, had biochemical features of the disease (see Table 1 for results).
The inheritance in this family is also compatible with an autosomal dominant mode.
Biochemical analysis
Routine biochemical measurements, including serum alkaline phosphatase, were carried out using an SMAC I\II analyser (Technicon, Tarrytown, NY, U.S.A.). Alkaline phosphatase activity was measured using pnitrophenyl phosphate as substrate with a 2-amino-2-methyl-1-propanol buffer, pH 10.3, at 30 mC. Urine phosphoethanolamine was measured using an amino acid analyser, with ion-exchange gradient HPLC on a Biochrom 20 Analyser (Pharmacia Biotech Ltd., Cambridge, U.K.). PP i was measured using a Sigma kit (Sigma, Poole, Dorset, U.K.), and serum pyridoxal 5h-phosphate was measured by HPLC at the Royal Gwent Hospital (Newport, Wales, U.K.).
DNA analysis
Genomic DNA was extracted from peripheral blood by standard phenol\chloroform techniques, and portions of 5 µg were digested with MspI or BclI (Life Technologies, Paisley, Scotland, U.K.). For one subject (Family 1, subject III-1), post-delivery placental tissue was used to obtain DNA. Following agarose-gel electrophoresis, the DNA was Southern-blotted on to a Hybond N nylon membrane (Amersham Pharmacia Biotech, Little Chalfont, Bucks., U.K.). The blots were hybridized with 10 ng of the 2.5 kb insert of the human TNSALP cDNA clone pS3-pS1 [10] labelled with [α-$#P]dCTP using the random-primer method. Post-hybridization washes were carried out with 0.1iSSC\0.1 % SDS at 65 mC (1iSSC is 0.15 M NaCl\0.015 M sodium citrate), and autoradiography was performed using Kodak X-AR film and intensifying screens at k70 mC for 2 days.
RESULTS
Biochemical analyses
The results of the biochemical analyses are summarized in Table 1 .
DNA analyses
The cDNA probe pS3-pS1 detects a BclI RFLP [11] and two MspI RFLPs [12] at the ALPL locus, which encodes TNSALP. The alleles of the BclI RFLP are detected as a band of 7.4 kb (allele B1) or a pair of bands of sizes 4.3 and 3.1 kb (allele B2) (Figure 1) . One MspI RFLP has allele sizes of 2.4 kb and 2.3 kb (alleles A1 and A2 respectively) ; the other has allele sizes of 1.98 kb and 1.9 kb (alleles A3 and A4 respectively) (Figure 2) . Consequently, four haplotypes with respect to MspI are possible (A1A3, A1A4, A2A3 and A2A4). Individuals from both families were typed with respect to the BclI and MspI RFLPs, and the data are presented in Table 1 .
Family 1
The proband (I-3) is homozygous for the B2 allele of the BclI RFLP, whereas her normal spouse is heterozygous. Hence the mutation segregates with the B2 allele, and the status of their affected child (II-2) is consistent with this, as she is also homozygous for the B2 allele. The granddaughter (III-1) is also homozygous for the B2 allele, although it is not clear which of her mother's two B2 alleles she has inherited. The family is not informative with respect to MspI haplotypes, although it is evident from the analysis of the proband and her daughter that the mutation segregates either with the A1A4 or the A2A4 haplotype. It would not be possible to determine disease status solely by DNA diagnosis in this family using these markers.
Family 2
The proband's father (I-2) is heterozygous for the BclI RFLP, as is his normal spouse (I-1). The affected offspring [II-2 and II-3 (proband)] inherited the B1 allele from both parents, and hence the mutation segregates with the paternal B1 allele. The unaffected child (II-1) inherited the B2 allele from both parents. For the MspI RFLPs, the father has the A1A3 and A1A4 haplotypes. The affected offspring inherited the A1A4 haplotype from their father and the A2A4 haplotype from their mother. Hence the mutation segregates with the paternal A1A4 haplotype. The unaffected child inherited the paternal A1A3 allele and the maternal A1A4 allele. Combining the data, the mutation causing hypophosphatasia in this family is on a chromosome with the BclI B1 allele and the MspI A1A4 haplotype (a B1A1A4 haplotype). On the basis of RFLP testing, there would be no doubts about diagnosis in the pedigree, as shown in Figures 1 and 2 .
The only marker system for which both families are informative is the BclI RFLP, and in the two cases the mutation segregates with a different allele (B2 in Family 1 and B1 in Family 2). This suggests that the mutations in these families are not identical, unless the same mutation has arisen more than once on different haplotypic backgrounds.
DISCUSSION
An accurate diagnosis of hypophosphatasia would be helpful in symptomatic individuals suspected of the disease, in possible healthy carriers and prenatally. Currently the diagnosis of hypophosphatasia is made on the basis of clinical features, subnormal alkaline phosphatase levels and raised levels of phosphorylated metabolites. Although the diagnosis is clear-cut in some individuals, in milder forms of hypophosphatasia the biochemical abnormalities may not be marked, and values often overlap with those in normal subjects [13] . In view of the plethora of methods available for measuring serum alkaline phosphatase, reference ranges can vary considerably, notably in children, especially at times of skeletal growth [14] . Although in children with very low levels of alkaline phosphatase the diagnosis of hypophosphatasia would be clear, in milder forms of the disease children may show a higher alkaline phosphatase level and, as Whyte [1] has pointed out, careful interpretation of results is needed. Alkaline phosphatase and phosphoethanolamine levels are known to vary with age, and this is also likely to be the case for PP i and pyridoxal 5h-phosphate levels. This adds further to diagnostic difficulties ; therefore definitive diagnostic tests using DNA-based methods would clearly be advantageous in this context.
Among the currently available methods in the U.K., the prenatal diagnosis of hypophosphatasia is made by measuring TNSALP levels in chorionic villus biopsies obtained in the first trimester [15, 16] . A combination of radiography and ultrasound inspection of the foetal skull and other skeletal morphometry is also used in the second trimester [17, 18] . Culture of cells from the amniotic fluid has also been used [19] . However, direct measurement of alkaline phosphatase levels in the amniotic fluid has produced variable results. This method is likely to produce possible errors, as different alkaline phosphatase isoenzymes, expressed by different alkaline phosphatase genes, are present in the amniotic fluid at different stages of pregnancy ; e.g. in the first trimester, intestinal alkaline phosphatase is present at its highest concentration [20] . It is not surprising that measurements of this type have produced inconsistent results [16] . Some caution has also been expressed with regard to the measurement of TNSALP levels in chorionic villus biopsies, as significant overlap can occur between normal and abnormal ranges [15] . The culture of amniotic fluid cells not only takes time, but may also produce results that overlap with normal values [16] . Since hypophosphatasia is the result of mutations at the ALPL locus, methods that utilize DNA analysis are likely to be diagnostically the most specific.
In the present study, RFLP analysis has, in some instances, distinguished between affected and nonaffected cases. In Family 1 it is clear that hypophosphatasia segregates with the B2 allele of the BclI RFLP. However, the two affected individuals, I-3 and II-2, are both homozygous for B2, which means that it is impossible to distinguish whether the normal or mutant allele has been inherited by individual III-1. Unfortunately, the family is not informative for the MspI RFLPs, and it remains impossible to diagnose hypophosphatasia in II-2hs offspring using RFLP inheritance as a criterion. The proband's unaffected nephew (II-3) is homozygous for the B1 allele, consistent with the biochemical data. Hence the BclI RFLP will not be of help in prenatal diagnoses in future offspring of II-2 (who has already made enquiries to this effect), but may be of value in the extended family.
In Family 2, hypophosphatasia segregates with the BclI B1 allele and the MspI A1A4 haplotype, consistent with the biochemical data. The two affected individuals in the second generation (II-2 and II-3) are homozygous for B1, but are heterozygous for A1A4\A2A4. Hence there is the future possibility of prenatal diagnoses on the basis of MspI haplotype inheritance, depending on the haplotypes carried by their potential partners. The success of this approach has been reported in a number of families [8, 12] , but clearly the ideal solution would be direct detection of the mutation.
The mode of inheritance in the different clinical types of hypophosphatasia is not uniform. In the perinatal and infantile types of the disorder, in which the subjects are often severely affected, the autosomal recessive mode of inheritance is well accepted [1, 11] . In the adult type, inheritance is thought to be autosomal dominant [21] [22] [23] , although there is clear evidence that some affected adult individuals are compound heterozygotes for recessive alleles [23, 24] . Such cases, however, would be expected to be sporadic, and not to exhibit the dominant inheritance pattern seen in the families presented here.
